Despite positive results from a Phase I/II trial of its investigational pandemic influenza vaccine, mRNA-1018, Moderna’s ...

Press release Launch of a capital increase with preferential subscription rights for nearly 5 million euros Issuance of new shares for an initial total amount of around €5.0 million, with shareholders ...

Soligenix (NASDAQ: SNGX) is spotlighting new interim data on HyBryte(TM) (synthetic hypericin) for early-stage cutaneous T-cell ly ...

The company is one of the first to receive a “platform technology designation,” which could speed the review of certain gene ...

Breast cancer study results impressed at this year’s meeting, but raised new questions. Doctors also wrestled with how best ...